Cedilla is developing novel small-molecule therapeutics directed to unrecognized allosteric binding sites, providing new ways to target key cancer drivers and treat life threatening diseases.
Proteins are functionally dynamic. Interactions within the cellular environment critically modulate their activity.
Mainstream approaches to drug discovery view proteins as static entities and focus on a single and simplified state.
Computational and structural protein models offer a limited view of drug targets.
As a result, many high-value targets have been deemed undruggable.
Cedilla is challenging this status quo.
Cedilla takes into account the native full-length protein with relevant post-translational modifications (PTMs), protein-protein interactions (PPIs), and sub-cellular localization.
Cedilla is uncovering novel ways to access key cancer drivers that have been considered undruggable.